Back to Search
Start Over
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer
- Source :
- Science Translational Medicine. 13
- Publication Year :
- 2021
- Publisher :
- American Association for the Advancement of Science (AAAS), 2021.
-
Abstract
- A subset of drug-resistant EGFR -mutant MET -amplified lung cancer switches oncogenic dependence to MET and is treatable with MET inhibitor monotherapy.
Details
- ISSN :
- 19466242 and 19466234
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Science Translational Medicine
- Accession number :
- edsair.doi...........6f7c7b3de9b86168add52ec03c24e84e